Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
Last trade$2.34
Day change-$0.145 (-5.85%)
Day range$2.28 – $2.52
Volume13,689
Market cap$13M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for NEUP.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for NEUP.
Recent news
Company coverage with links to the original publishers.
Monteverde & Associates PC is investigating four major M&A transactions on behalf of shareholders: Northrim Bancorp's merger with PBCO Financial Corporation, Neuphoria Therapeutics' merger with Scancell Holdings plc, Safety Insurance Group's sale to a Mapfre affiliate, and RE/MAX Holdings' sale to The Real Brokerage Inc. The firm encourages shareholders to contact them regarding potential concerns with these deals.
GoPro has retained financial advisers to explore a potential sale following unsolicited inquiries. Brookfield Asset Management acquired World Freight Company for $1.2 billion. Multiple companies announced strategic reviews including Neuphoria Therapeutics and XBP Global Holdings. YesCare Corp. and Spanish Broadcasting System filed for Chapter 11 bankruptcy. Other notable deals include Allegiant's $1.5 billion acquisition of Sun Country Airlines, LVMH's sale of Marc Jacobs for $850 million, and Cantaloupe Inc.'s acquisition by 365 Retail Markets for $848 million.
Neuphoria Therapeutics reported achieving last patient last visit milestone in AFFIRM-1 Phase 3 trial for BNC-210 in social anxiety disorder, with topline data expected in early Q4 2025. The company extended its cash runway through fiscal Q2 2027 and reported a reduced net loss compared to the previous year.
Neuphoria Therapeutics has completed target enrollment of 332 participants in its Phase 3 AFFIRM-1 trial for BNC-210, a potential treatment for social anxiety disorder, with initial Phase 3 data expected in early Q4 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.